PK/PD in Special Populations:
Over 50% of drug use in children are off label. The rate of hospitalization due to adverse drug effects is two times higher in elderly patients. To ensure safety and efficacy, significant efforts are needed to better understand the drug pharmacokinetics and pharmacodynamics in these vulnerable populations. My work has leveraged the quantitative knowledge of physiological and anatomical differences in children and elderly patients to investigate the dosing regimens of various drugs. I use pharmacokinetic and pharmacodynamic modeling approaches to help optimize drug dosing individualization and improve drug use in special populations.
Seeking PK/PD Analysis Support?
Email sinyin.lim@wisc.edu
Active grant information
1U01AG081482-01, National Institute on Aging. Role: Co-Investigator. PI: A Konopka, D Lamming. “Safer mTOR inhibition for human geroprotection” (2023-2027)
1R01HD116793-01, National Institute of Child Health and Human Development. Role: Co-Investigator. PI: M Harer. “Optimizing Caffeine Therapy for Hypoxia in Preterm Neonates: A Randomized Trial Assessing Efficacy, Acute Kidney and Brain Injury, Safety, and Pharmacokinetics” (2025-2030)
1U01AI192041-01, National Institute of Allergy and Infectious Diseases. Role: Co-Investigator. PI: A Garcia-Prats. “Re-evaluating the Duration in Children of TB Treatment (REDUCE TB): A Phase 2 Duration Randomized Trial” (2025-2030)